PALB2 and cancer: Furthermore, while these data support the value of pre-diagnostic awareness and high-risk screening to detect cancers early and reduce the need for chemotherapy, they also suggest that BRCA1/2 and PALB2 carriers should be counseled around the greater than 60% likelihood of requiring chemotherapy even if diagnosed with early-stage disease.